Diabetes News and Research

Latest Diabetes News and Research

Avid, Cardinal Health partner to detect Alzheimer's disease in living patients

Currently, Alzheimer's disease cannot be definitively diagnosed until after death, when a brain autopsy is performed on a patient and evidence of beta-amyloid plaque deposits in the brain – which are a characteristic pathology of the disease – can be found. Accurate diagnosis during life can be challenging, particularly in the early stages of Alzheimer's, when symptoms are mild and non-definitive. However, Avid Radiopharmaceuticals, Inc. and Cardinal Health are working together to change that.

26 Mar 2010

FDA Advisory Committee to review VIVUS' NDA for Qnexa

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration is tentatively scheduled to review the Company's New Drug Application for Qnexa® for the treatment of obesity on July 15, 2010.

26 Mar 2010

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Celera Corporation today announced the publication of data reporting that elderly (over age 70) carriers of the KIF6 gene variant with prior vascular disease received significant benefit from pravastatin (Pravachol®) therapy. Previous research has shown that a variant of the KIF6 gene, a member of the molecular motor protein kinesin family, is associated with up to a 55% increased risk of primary and recurrent coronary heart disease (CHD) events in the placebo arms of the clinical trials, and that this increased risk is virtually eliminated with statin therapy.

26 Mar 2010

Budget continues to ignore mental illness and sanctions deaths of young Ontarians

Suicide is the leading cause of non-accidental death in Ontario's youths aged 10 to 19, claiming the lives of our young people more than any other health-related cause. Mental illness is the strongest risk factor for suicide yet these youths cannot get treatment because of years of government underfunding.

26 Mar 2010

Lung transplant patients may one day benefit from synthetic peptide, researchers report

Lung transplant patients may one day benefit from a synthetic peptide that mimics the body's natural ability to reduce excess fluid accumulation, Medical College of Georgia researchers report.

26 Mar 2010

Fairbanks Institute for Healthy Communities introduces INbank biorepository

The Fairbanks Institute for Healthy Communities, the Indianapolis not-for-profit organization working to improve community health, announced today the creation of INbank™, a next generation biorepository that will provide scientists with an important resource for research on chronic diseases of aging.

26 Mar 2010

Roche NimbleGen' s microarray technologies help identify genes responsible for CRC

In a recently published study in the journal Genome Research, a team of scientists led by Dr. Shaying Zhao at the University of Georgia have developed a novel cross-species comparative genomics and oncology strategy for cancer driver gene discovery, using microarray technologies from Roche NimbleGen, that differs fundamentally from current approaches which focus on human cancers only.

26 Mar 2010

Working of master regulator protein phosphatase 1

Protein phosphorylation is a process by which proteins are flipped from one activation state to another. It is a crucial function for most living beings, since phosphorylation controls nearly every cellular process, including metabolism, gene transcription, cell-cycle progression, cytoskeletal rearrangement and cell movement.

26 Mar 2010

Medical conditions put seniors at high risk of unsubsidized medical prescription expenses

If you're older, a woman, and suffering from either dementia or diabetes, you are the most likely to be exposed to unsubsidized medication costs in the US. This is known as the coverage gap for enrollees of Medicare Part D - the US federal program which subsidizes the cost of prescription drugs for Medicare beneficiaries.

26 Mar 2010

Ontario's doctors commend government for taking steps to create comprehensive health care system

In the face of ongoing economic challenges, Ontario's doctors commend the government for taking the necessary steps to increase quality and efficiency in the health care system.

26 Mar 2010

Diabetes reached epidemic proportions in adult population of China: Study

A large population-based study of diabetes in China conducted by investigators from Tulane University and their colleagues in China has concluded that the disease has reached epidemic proportions in the adult population of China. The study estimates that 92.4 million adults age 20 or older (9.7 percent of the population) have diabetes and 148.2 million adults (15.5 percent) have prediabetes, a key risk factor for the development of overt diabetes and cardiovascular disease.

26 Mar 2010

New topical drug may help treat diabetic eye disease

Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.

26 Mar 2010

Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc. announced today the completion of its' pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. The Company expects to report results from this study within the coming weeks.

26 Mar 2010

Early screening for diabetes and kidney disease can improve health outcomes

Millions of Americans may have chronic kidney disease (CKD) and not know it, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX

Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.

26 Mar 2010

Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial

Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will continue enrolling to the preset goal of 2,000 patients. As part of a planned interim analysis, an independent Data Monitoring Committee (DMC) has evaluated efficacy and safety data on the first 1,500 subjects to complete the 28-day follow-up in the Phase III ACCESS trial.

26 Mar 2010

AVASTIN receives Health Canada approval for patients with GBM

Roche Canada announced today that Health Canada has approved AVASTIN(R) (bevacizumab), as a single agent, for the treatment of patients with glioblastoma multiforme, the most aggressive primary malignant brain tumour, after relapse or disease progression, following prior therapy.

26 Mar 2010

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

26 Mar 2010

DARA BioSciences announces the initiation of Phase I clinical study for DB959

DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.

26 Mar 2010

Diabetes News and Research

Latest Diabetes News and Research

Avid, Cardinal Health partner to detect Alzheimer's disease in living patients

FDA Advisory Committee to review VIVUS' NDA for Qnexa

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Budget continues to ignore mental illness and sanctions deaths of young Ontarians

Lung transplant patients may one day benefit from synthetic peptide, researchers report

Fairbanks Institute for Healthy Communities introduces INbank biorepository

Roche NimbleGen' s microarray technologies help identify genes responsible for CRC

Working of master regulator protein phosphatase 1

Medical conditions put seniors at high risk of unsubsidized medical prescription expenses

Ontario's doctors commend government for taking steps to create comprehensive health care system

Diabetes reached epidemic proportions in adult population of China: Study

New topical drug may help treat diabetic eye disease

Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule

Early screening for diabetes and kidney disease can improve health outcomes

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX

Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial

AVASTIN receives Health Canada approval for patients with GBM

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

DARA BioSciences announces the initiation of Phase I clinical study for DB959

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Diabetes News and Research

Latest Diabetes News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in